Advertisement
Advertisement
U.S. markets open in 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

PAVmed Inc. (PAVM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6100-0.0610 (-9.09%)
At close: 04:00PM EST
0.6200 +0.01 (+1.64%)
Pre-Market: 08:25AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.6710
Open0.6507
Bid0.6103 x 800
Ask0.7000 x 1200
Day's Range0.5911 - 0.6787
52 Week Range0.5800 - 3.6600
Volume966,065
Avg. Volume671,847
Market Cap57.16M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.7200
Earnings DateNov 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PAVM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PAVmed Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

    NEW YORK, December 01, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device ("EsoCheck") at the American Association for Cancer Research’s ("AACR") Special Conference: Precision Prevention, Early Detect

  • Business Wire

    PAVmed Provides Business Update and Third Quarter 2022 Financial Results

    NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.

  • Business Wire

    Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

    NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.

Advertisement
Advertisement